MCP-1 controls IL-17-promoted monocyte migration and M1 polarization in osteoarthritis
International Immunopharmacology · 2024-05 · 132 · 112016
DOI: 10.1016/j.intimp.2024.112016 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-05. Verfasst von Shang-Lin Hsieh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan; Minimally Invasive Spine and Joint Center, Buddhist Tzu Chi Gen…. Hauptthemen laut MEDLINE: Cell Movement, Chemokine CCL2, Interleukin-17, Macrophages. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: China Medical University, National Science and Technology Council, China Medical University Hospital.
Abstract (Originalsprache)
Osteoarthritis (OA) is a low-grade inflammatory joint illness in which monocytes migrate and infiltrate synovial tissue, differentiating into the pro-inflammatory M1 macrophage phenotype. IL-17 is a proinflammatory mediator principally generated by Th17 cells, which is elevated in OA patients; nevertheless, investigators have yet to elucidate the function of IL-17 in M1 polarization during OA development. Our analysis of clinical tissues and results from the open online dataset discovered that the level of M1 macrophage markers is elevated in human OA tissue samples than in normal tissue. High-throughput screening demonstrated that MCP-1 is a potential candidate factor after IL-17 treatment in OA synovial fibroblasts (OASFs). Immunohistochemistry data revealed that the level of MCP-1 is higher in humans and mice with OA than in normal tissues. IL-17 stimulation facilitates MCP-1-dependent macrophage polarization to the M1 phenotype. It also appears that IL-17 enhances MCP-1 synthesis in human OASFs, enhancing monocyte migration via the JAK and STAT3 signaling cascades. Our findings indicate the IL-17/MCP-1 axis as a novel strategy for the remedy of OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan; Minimally Invasive Spine and Joint Center, Buddhist Tzu Chi General Hospital Taichung Branch, Taichung, Taiwan.
- Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan.
- Translational Medicine Center, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan.
- Department of Sports Medicine, College of Health Care, China Medical University, Taichung, Taiwan; Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan.
- Department of Sports Medicine, College of Health Care, China Medical University, Taichung, Taiwan; Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan; Department of Orthopedic Surgery,…
Förderung
- China Medical University
- National Science and Technology Council
- China Medical University Hospital
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Hsieh, S. L., Yang, S. Y., Lin, C. Y., He, X. Y., Tsai, C. H., Fong, Y. C., Lo, Y. S., & Tang, C. H. (2024). MCP-1 controls IL-17-promoted monocyte migration and M1 polarization in osteoarthritis. International Immunopharmacology, 132, 112016. https://doi.org/10.1016/j.intimp.2024.112016
Vancouver
Hsieh SL, Yang SY, Lin CY, He XY, Tsai CH, Fong YC, et al. MCP-1 controls IL-17-promoted monocyte migration and M1 polarization in osteoarthritis. International Immunopharmacology. 2024;132:112016. doi:10.1016/j.intimp.2024.112016
BibTeX
@article{Hsieh2024,
author = {Hsieh, Shang-Lin and Yang, Shang-Yu and Lin, Chih-Yang and He, Xiu-Yuan and Tsai, Chun-Hao and Fong, Yi-Chin and Lo, Yuan-Shun and Tang, Chih-Hsin},
title = {MCP-1 controls IL-17-promoted monocyte migration and M1 polarization in osteoarthritis},
journal = {International Immunopharmacology},
year = {2024},
volume = {132},
pages = {112016},
doi = {10.1016/j.intimp.2024.112016}
}
EUVIMED